Welcome to LookChem.com Sign In|Join Free

CAS

  • or
GNF179 Metabolite is a chemical compound that is a metabolite of GNF179, a potent and specific small molecule inhibitor of mTOR kinase. It is involved in the regulation of multiple cellular processes, including protein synthesis, autophagy, and cell proliferation.
Used in Pharmaceutical Industry:
GNF179 Metabolite is used as a research tool for understanding mTOR signaling and developing new cancer treatments. It may contribute to the pharmacological effects of the parent compound, GNF179, which is a key regulator of cellular growth and metabolism.
Used in Cancer Therapy:
GNF179 Metabolite is used as a potential therapeutic agent for cancer treatment. It has the potential to be an important tool in understanding mTOR signaling and developing new cancer treatments.

1310455-86-7 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 2-(4-fluorophenyl)-8,8-dimethyl-6,7-dihydro-5H-imidazo[1,2-a]pyrazine

    Cas No: 1310455-86-7

  • USD $ 1.9-2.9 / Gram

  • 100 Gram

  • 1000 Metric Ton/Month

  • Chemlyte Solutions
  • Contact Supplier
  • 1310455-86-7 Structure
  • Basic information

    1. Product Name: GNF179 Metabolite
    2. Synonyms: GNF179 Metabolite;2-(4-fluorophenyl)-8,8-dimethyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine;EOS-60885
    3. CAS NO:1310455-86-7
    4. Molecular Formula: C14H16FN3
    5. Molecular Weight: 245.2953432
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 1310455-86-7.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: 428.6±40.0 °C(Predicted)
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: 1.23±0.1 g/cm3(Predicted)
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. PKA: 8.43±0.40(Predicted)
    10. CAS DataBase Reference: GNF179 Metabolite(CAS DataBase Reference)
    11. NIST Chemistry Reference: GNF179 Metabolite(1310455-86-7)
    12. EPA Substance Registry System: GNF179 Metabolite(1310455-86-7)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1310455-86-7(Hazardous Substances Data)

1310455-86-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1310455-86-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,1,0,4,5 and 5 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1310455-86:
(9*1)+(8*3)+(7*1)+(6*0)+(5*4)+(4*5)+(3*5)+(2*8)+(1*6)=117
117 % 10 = 7
So 1310455-86-7 is a valid CAS Registry Number.

1310455-86-7Relevant articles and documents

An efficient, stereocontrolled and versatile synthetic route to bicyclic partially saturated privileged scaffolds

Bond, Andrew D.,Hanby, Abigail R.,King, Thomas A.,Moss, Thomas A.,Sore, Hannah F.,Spring, David R.,Stewart, Hannah L.

, p. 6818 - 6821 (2020/07/04)

Herein, we describe the development of a simple, high yielding and stereocontrolled strategy for the synthesis of a series of triazolopiperazines and other biologically relevant fused scaffolds from optically active amino acids. This route was applied to the synthesis of 22 scaffolds containing new, previously inaccessible vectors and used to access a novel analogue of ganaplacide.

Imidazolopiperazines: Lead optimization of the second-generation antimalarial agents

Nagle, Advait,Wu, Tao,Kuhen, Kelli,Gagaring, Kerstin,Borboa, Rachel,Francek, Caroline,Chen, Zhong,Plouffe, David,Lin, Xuena,Caldwell, Christopher,Ek, Jared,Skolnik, Suzanne,Liu, Fenghua,Wang, Jianling,Chang, Jonathan,Li, Chun,Liu, Bo,Hollenbeck, Thomas,Tuntland, Tove,Isbell, John,Chuan, Tiffany,Alper, Philip B.,Fischli, Christoph,Brun, Reto,Lakshminarayana, Suresh B.,Rottmann, Matthias,Diagana, Thierry T.,Winzeler, Elizabeth A.,Glynne, Richard,Tully, David C.,Chatterjee, Arnab K.

, p. 4244 - 4273 (2012/07/03)

On the basis of the initial success of optimization of a novel series of imidazolopiperazines, a second generation of compounds involving changes in the core piperazine ring was synthesized to improve antimalarial properties. These changes were carried out to further improve the potency and metabolic stability of the compounds by leveraging the outcome of a set of in vitro metabolic identification studies. The optimized 8,8-dimethyl imidazolopiperazine analogues exhibited improved potency, in vitro metabolic stability profile and, as a result, enhanced oral exposure in vivo in mice. The optimized compounds were found to be more efficacious than the current antimalarials in a malaria mouse model. They exhibit moderate oral exposure in rat pharmacokinetic studies to achieve sufficient multiples of the oral exposure at the efficacious dose in toxicology studies.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1310455-86-7